HighTower Advisors LLC Takes $607,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

HighTower Advisors LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,485 shares of the medical equipment provider's stock, valued at approximately $607,000.

Several other institutional investors have also recently made changes to their positions in the company. Farallon Capital Management LLC grew its holdings in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock worth $182,999,000 after acquiring an additional 796,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after purchasing an additional 19,071 shares during the period. Swedbank AB boosted its stake in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock valued at $79,266,000 after purchasing an additional 125,843 shares in the last quarter. LSV Asset Management increased its holdings in Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider's stock valued at $51,462,000 after buying an additional 139,647 shares during the period. Finally, Clearbridge Investments LLC increased its holdings in Lantheus by 7.6% during the second quarter. Clearbridge Investments LLC now owns 560,609 shares of the medical equipment provider's stock valued at $45,011,000 after buying an additional 39,369 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LNTH. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday. They set a "buy" rating and a $143.00 target price for the company. Truist Financial restated a "buy" rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. JMP Securities decreased their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday, November 7th. Finally, StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $131.86.

Lantheus Price Performance

Lantheus stock traded down $2.65 during midday trading on Friday, reaching $89.29. The company's stock had a trading volume of 2,166,547 shares, compared to its average volume of 1,019,253. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market capitalization of $6.21 billion, a P/E ratio of 14.86 and a beta of 0.45. The stock's 50-day simple moving average is $96.63 and its 200-day simple moving average is $98.18.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.